Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.
Reding MT, Lalezari S, Kenet G, Di Minno G, Ducore J, Solms A, Shah A, Holme PA, Poulsen LH, Meijer K, Simpson M, Mancuso ME. Reding MT, et al. Among authors: simpson m. Drugs R D. 2024 Dec 20. doi: 10.1007/s40268-024-00494-2. Online ahead of print. Drugs R D. 2024. PMID: 39702563 No abstract available.
Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.
Reding MT, Lalezari S, Kenet G, Di Minno G, Ducore J, Solms A, Shah A, Holme PA, Poulsen LH, Meijer K, Simpson M, Mancuso ME. Reding MT, et al. Among authors: simpson m. Drugs R D. 2024 Sep;24(3):359-381. doi: 10.1007/s40268-024-00481-7. Epub 2024 Aug 20. Drugs R D. 2024. PMID: 39162954 Free PMC article. Review.
Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.
Olivieri M, Simpson M, Yan S, Fedorovsky J, Zhang X, Tomic R, Pinachyan K, Mancuso ME. Olivieri M, et al. Among authors: simpson m. Curr Med Res Opin. 2022 Jul;38(7):1133-1139. doi: 10.1080/03007995.2022.2062180. Epub 2022 May 2. Curr Med Res Opin. 2022. PMID: 35387548 Free article.
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR. Peyvandi F, et al. Among authors: simpson m. N Engl J Med. 2016 May 26;374(21):2054-64. doi: 10.1056/NEJMoa1516437. N Engl J Med. 2016. PMID: 27223147 Free article. Clinical Trial.
Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
Ducore J, Lawrence JB, Simpson M, Boggio L, Bellon A, Burggraaf J, Stevens J, Moerland M, Frieling J, Reijers J, Wang M. Ducore J, et al. Among authors: simpson m. Haemophilia. 2017 Nov;23(6):844-851. doi: 10.1111/hae.13357. Epub 2017 Oct 5. Haemophilia. 2017. PMID: 28984010 Clinical Trial.
2,167 results